A new cross-Canada study has found that breast and prostate cancer treatment can foster bone loss. The scientists explain how loss of bone mass might affect 46,000 people diagnosed with breast and prostate cancer each year and place them at increased risk for osteoporosis and fractures.
“Our study also looked at possible medications that can reverse or halt bone loss,” says Dr. Fred Saad, lead author and director of urologic oncology.
“Bone is a dynamic tissue which undergoes a cyclic process of breaking down and rebuilding,” adds Dr. Saad. “Medications called bisphosphonates help with the rebuilding process and have been successfully used to combat osteoporosis, which is good news for cancer patients.”
Dr. Saad and colleagues evaluated data from more than 3,500 breast and prostate cancer studies. They concluded that breast cancer patients treated with aromatase inhibitors were more likely to have bone loss and fractures compared to patients who didn’t receive the therapy.
Similarly, men who received androgen deprivation therapy to treat their prostate cancer had an increased risk of bone disorders. Although the numbers vary from one study to the next (from five to 45 percent), an elevated risk is consistently observed.
Read more at ScienceDaily
